

### AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application.

#### Listing of Claims:

34. **(currently amended)** An oligopeptide having the amino acid sequence:  
Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO:13).
35. **(original)** The oligopeptide according to Claim 2 wherein one or more of the amino acids of said oligopeptide are D isomers.
36. **(original)** The oligopeptide according to Claim 3, wherein all the amino acids of said oligopeptide, other than glycine, are D isomers.
37. **(original)** The oligopeptide according to any one of Claims 1 to 3, wherein the terminal carboxyl group of said oligopeptide is amidated.
38. **(original)** The oligopeptide according to Claim 5, wherein said terminal carboxyl group is the acetate salt of an amide.
39. **(original)** An oligopeptide having the structural formula:  
H-(D)Arg-(D)nL-(D)nL-(D)nL-(D)Arg-(D)nL-(D)nL-(D)nL-Gly-(D)Tyr-NH<sub>2</sub>.
40. **(original)** A pharmaceutical composition comprising an oligopeptide according to any one of Claims 1 to 7 and a pharmaceutically acceptable medium.
41. **(original)** The pharmaceutical composition according to Claim 8, wherein said pharmaceutically acceptable medium comprises an excipient.
42. **(original)** The pharmaceutical composition according to Claim 9, wherein said excipient comprises mannitol.